- Letter to the Editor
- Open Access
AGER expression and alternative splicing in bronchial biopsies of smokers and never smokers
© The Author(s). 2019
- Received: 24 October 2018
- Accepted: 29 March 2019
- Published: 10 April 2019
Cigarette smoking is one of the major risk factors for the development of chronic obstructive pulmonary disease (COPD). Evidence is accumulating that Receptor for Advanced Glycation-End products (RAGE)-signaling is a key pathway in the pathophysiology of COPD. To date, it is unknown how smoking affects RAGE expression. In the current study, we investigated the effect of smoking on AGER, the gene encoding RAGE, expression and on alternative splicing of AGER. To this end, we conducted RNA-Seq on bronchial biopsies for asymptomatic smokers (n = 36) and never smokers (n = 40). Total AGER gene expression was accessed using DESeq2, while alternative splicing was investigated by measuring the number of specific split reads spanning exon-exon junctions and the total split reads. One of the major isoforms of RAGE is endogenous soluble (es) RAGE, an anti-inflammatory decoy receptor, making up for approximately 10% of the total amount of soluble (s)RAGE. We found that smokers show decreased total gene expression of AGER in bronchial biopsies, while the relative abundance of the esRAGE isoform is increased. Furthermore, no difference in the serum levels of total sRAGE were observed between smokers and non-smokers. Our data indicates that smoking initiates a protective anti-inflammatory mechanism with decreased expression of the pro-inflammatory gene AGER and increased relative abundance of the anti-inflammatory isoform esRAGE.
- Cigarette smoking
- Alternative splicing
To date, cigarette smoking is one of the biggest public health threats worldwide, being causative for the dead of approximately 7 million people every year, according to the World Health Organization (WHO). Smoking can lead to multiple diseases, including cardiovascular diseases, lung cancer and chronic obstructive pulmonary disease (COPD). The underlying mechanisms of these diseases are still largely unknown. However, there seems to be one molecular pathway which connects the three diseases, the receptor for advanced glycation end-products (RAGE) signaling pathway. RAGE is a pro-inflammatory pattern recognition receptor, which is mainly expressed by type I alveolar cells. The freely circulating soluble form of RAGE (sRAGE), inhibits RAGE signaling by binding RAGE ligands and preventing homo-dimerization of RAGE, necessary for activation. sRAGE can be formed by proteolytic cleavage or by alternative splicing. In the latter case the transmembrane domain, encoded by exon 10 of the gene encoding RAGE, AGER, is spliced out, resulting in the endogenous soluble form of RAGE (esRAGE), which passes the cell membrane and is released into the extracellular space upon translation.
In cardiovascular diseases it has been shown that RAGE signaling triggers and maintains the inflammatory state, and sRAGE can be used as a biomarker for the development of cardiovascular diseases , while in lung cancer RAGE expression may be beneficial, acting as a tumor-suppressor , However, the role of RAGE signaling is best characterized in COPD. The gene encoding RAGE, has been shown to be a susceptibility gene for COPD . Furthermore, sRAGE levels are decreased in COPD patients , while the levels of several RAGE ligands are increased both locally and systemically , indicating increased RAGE signaling. However, the effect of smoking on RAGE signaling is less well studied. It was shown that stimulation of gingival carcinoma epithelial cells with cigarette smoke extract (CSE) increases RAGE expression and the subsequent inflammatory reaction and induces oral squamous cell carcinoma cell invasion . Furthermore, it was shown that RAGE knock-out mice had reduced cigarette smoke-induced neutrophilic airway inflammation . However, there is less consensus about the effect of smoking on the circulating sRAGE levels, with some studies reporting no significant differences in serum sRAGE levels between smokers and never smokers , while other studies show a decreased level of sRAGE in serum of smokers . One study even showed an increase in the serum sRAGE levels of smokers compared to never smokers . In the current study we investigated the gene expression levels of AGER in lung tissue of smokers and never smokers and subsequently evaluated the level of alternative splicing in these individuals. Alternative splicing was measured using a novel, in house developed technique, based on comparing the number of specific split reads spanning exon-exon junctions to the total split reads per gene.
Here, we showed a significant decrease of total AGER expression in smokers compared to never smokers (Fig. 1b, smokers 1.92 ± 0.03 fpkm, never smokers 2.48 ± 0.02 fpkm, Mann Whitney-U test, p = 0.006). To investigate whether smoking affects the expression of endogenous soluble RAGE (esRAGE), all splicing events within the AGER gene were measured. We were able to detect all annotated intron splicing sites, an extension of exon 4 and the splicing of exon 10 which leads to the production of esRAGE (Fig. 1c). For all normal intron splicing sites and the alternative splice variant leading to an extension of exon 4, we did not observe any differences between smokers and never smokers (Fig. 1d). Interestingly, the splicing of exon 10 leading to the production of esRAGE was found to be increased within smokers (Fig. 1d-e, smokers 3.55 ± 0.12%, never smokers 2.44 ± 0.09%, Mann Whitney-U test, P = 0.03). Thus, the total expression of AGER is decreased in bronchial tissue of smokers, whereas the fraction of RAGE which leads to esRAGE is increased.
While studies on the effect of smoking on RAGE expression are limited, in vitro and murine studies have shown that exposure of lung epithelial cells to cigarette smoke extract or mice to cigarette smoke increased the expression of RAGE . Moreover, in a study investigating the RAGE expression in never smokers and active smokers using immunohistochemistry, an increase in RAGE expression was shown in mucosal cells specifically . Previously, up to 19 different alternative splice variants of AGER were detected on mRNA level in in vitro cultured human cells . In the current study, we employed a novel technique to detect alternative splice variants of AGER in human bronchial biopsies. Here, we were able to detect two alternative splice variants of RAGE, an elongation of the fourth exon and the splicing out of exon 10. Our study is the first to show differences in alternative splicing of AGER in smokers and never smokers. Here, it was shown that the expression of the pro-inflammatory RAGE receptor decreases and the relative portion of AGER expression which leads to the production of the anti-inflammatory decoy receptor esRAGE, increases. This suggests an anti-inflammatory mechanism to protect against an exaggerated immune reaction upon smoke exposure. Dysregulation of these anti-inflammatory mechanisms may trigger smoke-related diseases, including cardiovascular diseases, lung cancer and COPD. However, in the current population we also found that CD8+ T-cells were increased in current smokers compared to never-smokers (data not shown), as low levels of AGER expression have been observed in CD8+ T-cells before, we cannot exclude the possibility of enhanced splicing of the transcript that leads to esRAGE in CD8+ T-cells, influencing our results.
In summary, this is the first study investigating the expression of all splice sites within the AGER gene in relation to the total AGER gene expression. Here, we showed that although smokers have lowered total AGER expression, the portion of AGER, which leads to the production of the anti-inflammatory esRAGE protein is increased. Our study provides new insight in the molecular mechanisms of the human body to protect against the harmful effects of cigarette smoking. Upon dysregulation of these processes the susceptibility for smoke-induced diseases may increase and restoring the balance in the RAGE pathway may be utilized as potential therapeutic target in several smoke-related pathologies.
This work was supported by Lung Foundation Netherlands (project: 6.2.15.044JO), Noordelijke CARA stichting (project: 2016/01) and GlaxoSmithKline.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Conception, design of study: AF, MvdB, NHTtH, SDP, Acquisition of data: AF, CJV, VG, SDP, Analysis of data: AF, CJV, VG, SDP, Drafting of manuscript: AF, SDP, Revising manuscript: AF, MvdB, NHTtH, SDP, Approval of submission: AF, MvdB, CJV, NHTtH, VG, SDP. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Samples were used from the ‘A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects (NORM)’ study which has been registered on ClinicalTrials.gov with the identifier code: NCT00848406 and the medical ethic committee approval code: METc2009007. All study protocols were approved by the medical ethic committee of the University Medical Center Groningen (UMCG), Groningen, The Netherlands and all subjects provided written informed consent. Furthermore, all clinical procedures were performed according to the standards set by the latest Declaration of Helsinki.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Prasad K, Dhar I, Caspar-Bell G. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol [Internet]. 2015;24:75–80 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26060376.Google Scholar
- Wu S, Mao L, Li Y, Yin Y, Yuan W, Chen Y, et al. RAGE may act as a tumour suppressor to regulate lung cancer development. Gene [Internet]. 2018;651:86–93 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29421442.View ArticleGoogle Scholar
- Castaldi PJ, Cho MH, Litonjua AA, Bakke P, Gulsvik A, Lomas DA, et al. The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. Am J Respir Cell Mol Biol [Internet]. 2011;45:1147–53 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21659657.View ArticleGoogle Scholar
- Hoonhorst SJM, Lo Tam Loi AT, Pouwels SD, Faiz A, Telenga ED, van den Berge M, et al. Advanced glycation endproducts and their receptor in different body compartments in COPD. Respir Res [Internet]. 2016;17:46 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27117828.View ArticleGoogle Scholar
- Pouwels SD, Heijink IH, ten Hacken NHT, Vandenabeele P, Krysko DV, Nawijn MC, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol [Internet]. 2014;7:215–26 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24150257.View ArticleGoogle Scholar
- Chapman S, Mick M, Hall P, Mejia C, Sue S, Abdul Wase B, et al. Cigarette smoke extract induces oral squamous cell carcinoma cell invasion in a receptor for advanced glycation end-products-dependent manner. Eur J Oral Sci [Internet]. 2018;126:33–40 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29226456.View ArticleGoogle Scholar
- Wolf L, Herr C, Niederstraßer J, Beisswenger C, Bals R. Receptor for advanced glycation endproducts (RAGE) maintains pulmonary sructure and regulates the response to cigarette smoke. PLoS One [Internet]. 2017;12:e0180092 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28678851.View ArticleGoogle Scholar
- Caram LM de O, Ferrari R, Nogueira DL, Oliveira M, Francisqueti FV, Tanni SE, et al. Tumor necrosis factor receptor 2 as a possible marker of COPD in smokers and ex-smokers. Int J Chron Obstruct Pulmon Dis [Internet]. 2017;12:2015–21 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28744116.View ArticleGoogle Scholar
- Gopal P, Reynaert NL, Scheijen JLJM, Schalkwijk CG, Franssen FME, Wouters EFM, et al. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res [Internet]. 2014;15:24 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24564838.View ArticleGoogle Scholar
- Biswas SK, Mudi SR, Mollah FH, Bierhaus A, Arslan MI. Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects. Diabetes Vasc Dis Res [Internet]. 2013;10:380–2 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23520177.View ArticleGoogle Scholar
- Imkamp K, Berg M, Vermeulen CJ, Heijink IH, Guryev V, Kerstjens HAM, et al. Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression quantitative trait loci. J Allergy Clin Immunol [Internet]. 2018;142:314–317.e15 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29522853.View ArticleGoogle Scholar
- Robinson AB, Stogsdill JA, Lewis JB, Wood TT, Reynolds PR. RAGE and tobacco smoke: insights into modeling chronic obstructive pulmonary disease. Front Physiol [Internet]. 2012;3:301 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22934052.Google Scholar